Regeneron EVP McCourt sells 2,346 shares

Regeneron’s EVP Commercial reported selling 2,346 REGN shares in early September 2026 under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. (REGN) executive vice president of Commercial, Marion McCourt, reported open-market sales of company common stock under a Rule 10b5-1 trading plan. On September 3, 2026, she sold 1,131 shares at $857.39 per share, and on September 2, 2026, she sold 1,215 shares at $850.00 per share. A separate entry reports 219 shares of common stock held indirectly through a 401(k) plan as of September 2, 2026.

Insider Trade Summary 10b5-1

Net Seller: 2,346 shares

Net Sell 3 txns

Insider McCourt Marion

Role EVP Commercial

Sold 2,346 shs ($2.00M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,131	$857.39	$970K
Sale	Common Stock F1	1,215	$850.00	$1.03M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 12,003 shares (Direct); Common Stock — 219 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.

Key Figures

Shares sold September 3, 2026: 1,131 shares Price per share September 3, 2026 sale: $857.39 per share Shares sold September 2, 2026: 1,215 shares +4 more

7 metrics

Shares sold September 3, 2026 1,131 shares Regeneron common stock sold by Marion McCourt on September 3, 2026

Price per share September 3, 2026 sale $857.39 per share Sale of 1,131 shares of Regeneron common stock

Shares sold September 2, 2026 1,215 shares Regeneron common stock sold by Marion McCourt on September 2, 2026

Price per share September 2, 2026 sale $850.00 per share Sale of 1,215 shares of Regeneron common stock

Total shares sold in reported transactions 2,346 shares Combined sales on September 2 and 3, 2026 by Marion McCourt

Indirect holdings via 401(k) plan 219 shares Regeneron common stock held indirectly as of September 2, 2026

Rule 10b5-1 plan adoption date February 17, 2026 Plan intended to comply with Rule 10b5-1(c) for the reported dispositions

Key Terms

Rule 10b5-1(c), 401(k) Plan, open market or private transaction

3 terms

Rule 10b5-1(c) regulatory

"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

401(k) Plan financial

"Common stock reported as held indirectly by 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

open market or private transaction financial

"Sale in open market or private transaction of Regeneron common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did REGN’s executive report in this Form 4?

The executive vice president of Commercial, Marion McCourt, reported two sales totaling 2,346 shares of Regeneron common stock on September 2 and 3, 2026, plus an updated indirect holding of 219 shares in a 401(k) plan as of September 2, 2026.

At what prices were the REGN shares sold by Marion McCourt?

On September 3, 2026, Marion McCourt sold 1,131 REGN shares at $857.39 per share. On September 2, 2026, she sold 1,215 shares at $850.00 per share, both reported as open-market or private transactions in Regeneron common stock.

How many REGN shares did Marion McCourt sell in total in this filing?

The filing reports that Marion McCourt sold a total of 2,346 shares of Regeneron common stock, consisting of 1,215 shares sold on September 2, 2026, and 1,131 shares sold on September 3, 2026, in open-market or private transactions.

Were the REGN insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the dispositions were made pursuant to a plan intended to comply with Rule 10b5-1(c) that was adopted on February 17, 2026, and the filing indicates the Rule 10b5-1 plan status as affirmed.

What indirect REGN holdings does Marion McCourt report?

As of September 2, 2026, Marion McCourt reports 219 shares of Regeneron common stock held indirectly through a 401(k) plan. This is shown separately from her directly held shares involved in the reported sales.

Does the Form 4 state Marion McCourt’s total REGN holdings after these sales?

The Form 4 provides an updated figure of 219 indirectly held shares in a 401(k) plan as of September 2, 2026, but it does not state a total number of directly held shares following the reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:00 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCourt Marion

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Commercial

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		1,215	D	$850	13,134	D
Common Stock	09/03/2026		S(1)		1,131	D	$857.39	12,003	D
Common Stock								219	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.

	/s/ Marion McCourt	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)